Searched for
BETAPHARM
Dr Reddy's launches migraine management device in EuropeThe launch marks the company's entry into digital therapeutics in Europe, the Hyderabad-based drug major said in a statement. Nerivio is ap...- Buyouts unlikely to harm debt-free Lupin's healthWith no new blockbuster drugs going off patent in the near term, generic pharma companies have to explore new areas of growth like specialt...
- Betapharm to pressure profitability for 3 yrs: Dr Reddy's'There will be a significant growth in top-line and the company will participate in more tenders in Germany to mitigate the margin erosion.'
- Dr Reddy's to restructure German subsi BetapharmPharma major Dr Reddy's Laboratories (DRL) on Friday said it was restructuring German subsidiary Betapharm for better results in the future.
- No plan to sell domestic formulations business: Dr Reddy'sPharma major Dr Reddy's Laboratories Ltd (DRL) on Friday said it was restructuring German subsidiary Betapharm for better results in future...
- Dr Reddy's nets Rs 167 crore in Q4Dr Reddy’s Laboratories bounced back into profit for the three months ended March, helped by the absence of any further provisioning for lo...
- Non-regulated markets, leverage to pep up growthAt Rs 860 crore, the one-time write-off of goodwill of Dr Reddy's Laboratories' German subsidiary, Betapharm, has severely impacted its con...
- Growth in US, local market to pep up DRLDr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen ...
- Reddy's (betapharm) receives preliminary results on AOK tender in GermanyThe tender procedure is yet to be concluded and is expected to face the potential legal objections by several companies.
- Pricing pressure in US, Germany hits DRL profitDr Reddy’s Laboratories (DRL), country’s second-largest pharma company in terms of sales, has reported a worst-than-expected drop of 51% in...
- Dr Reddy's could face margin pressure in GermanyLeading Indian drug makers with a large presence in Germany could face substantial pressure on margins following a recent tender by a Germa...
- DRL describes Ranbaxy, Daiichi deal as path breakingDr Reddy's Laboratory, which defeated Ranbaxy in acquiring German company Betapharm, today said the Ranbaxy-Daiichi deal is "path breaking".
- Dr Reddy's plans to file 20 new drug applicationsDr Reddy’s Laboratories is betting on the US market and plans to file about 20 more ANDAs (Abbreviated New Drug Applications) in 2008. Reso...
- DRL bets on India plan for German armDr Reddy’s Laboratories (DRL) aims to shift production of about a dozen top-selling products of its German arm Betapharm to India by July 2...
- Dr Reddy's in race for US Par PharmaDr Reddy’s Laboratories is in the race with three other Indian drug majors to acquire US-based generic drug maker Par Pharma.
- After strong Q1, Ranbaxy reclaims numero uno slotRanbaxy has reclaimed the top slot as the largest pharma company in India from Dr Reddy’s Laboratories.
- Dr Reddy's gets a shot in the armDr Reddy’s Laboratories’ performance in FY07 has got a boost from selling authorised generics and revenues from its various acquisitions.
- Bumps ahead on M&A streetIndian companies will look for bigger acquisition opportunities in the New Year spurred by rising economic growth.
- DRL can use ADS mop-up to slash debt, fund acquisitionsDr Reddy’s Labs’ ADS issue could allow the domestic pharmaceutical major to raise around $235m (Rs 1,060 crore), taking into consideration ...
- Dr Reddy's plans fund raising from overseas marketHyderabad-based drugmaker Dr Reddy's is planning to raise funds from overseas market to finance its inorganic growth strategy.
Load More- Dr Reddy's to restructure German subsi Betapharm
